Pharmaceuticals

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

A major lab expansion in Massachusetts aims to slash preclinical timelines for the most promising new cancer treatments, including advanced radiotherapies.

Taiwan's PharmaEssentia is building a new U.S. facility in Puerto Rico, a move set to bolster drug supply chains and deepen US-Taiwan economic ties.

As a critical FDA drug safety reporting deadline looms, a new cloud tool helps smaller biotech and pharma firms avoid costly penalties and level the field.

Clinical AI launches MAIA™ on Google Cloud Marketplace, using Gemini AI to solve the patient enrollment crisis that stalls 80% of medical studies.

A new tool reveals how a federal drug program may be inflating healthcare costs for businesses, intensifying the debate over transparency and reform.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

A pivotal clinical trial for PMM2-CDG, a devastating genetic disorder with no approved treatments, has completed enrollment, offering hope to thousands.

Century Health and VCU are building a massive AI-driven database to decode steatotic liver disease, a silent epidemic affecting nearly 2 billion people.

After 40 years as a silent partner to global brands, Intercon Chemical is launching its own high-stakes medical cleaning lines to meet new safety standards.